Efficacy and safety of pemafibrate as add-on therapy to pitavastatin (Trial A) or any statin (Trial B)

Results strongly support the favourable benefit-to-risk ratio of pemafibrate add-on therapy in combination with statin treatment.

Please login or create a FREE account to view this content

Educational partners and supporters

Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc. Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc. Ionis Logo

Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc. Kowa Logo